Actinogen Presentation & Planned Conference Call
Filed with ASX · · 31 pages · English
Sydney, 15 October 2020. Actinogen Medical ASX: ACW (‘ACW’ or ‘the Company’) is pleased to advise that Dr. Bill Ketelbey, CEO and MD of Actinogen, will provide an update on the clinical development plans for Xanamem during a conference call on Monday, 19 October 2020 at 11:00am (AEDT). Dr. Ketelbey will provide an overview of the new indication in Fragile X syndrome, the planned Alzheimer’s diseas
Actinogen Medical Limited on 6ix
In the deck
Story so far
Earlier from Actinogen Medical
- Proposed issue of Securities - ACW
- ACW announces two clinical trials & launches capital raising
- Appendix 4E & Annual Report
- Market Update COVID-19
- December 2019 Quarterly Update
Later from Actinogen Medical
- Offer Booklet
- R&D Tax Incentive Rebate received of A$2.9 million
- ACW to initiate XanaFX clinical trial in Fragile X syndrome
- FDA IND Update
- Actinogen files new patent applications
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical